{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:09:13Z","timestamp":1780088953007,"version":"3.54.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.msard.2018.06.002","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T23:10:27Z","timestamp":1530141027000},"page":"123-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9049-753X","authenticated-orcid":false,"given":"Julian","family":"Gold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-9070","authenticated-orcid":false,"given":"Monica","family":"Marta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute C.","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tove","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Altmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Holden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Adiutori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"MacManus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Yousry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9293-8893","authenticated-orcid":false,"given":"Klaus","family":"Schmierer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-1700","authenticated-orcid":false,"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"February","key":"10.1016\/j.msard.2018.06.002_bib0001","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","article-title":"Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis","volume":"16","author":"Baker","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2018.06.002_bib0002","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/rmv.622","article-title":"Vilardell-Torres M: molecular mechanisms mediated by human endogenous retroviruses (HERVs) in autoimmunity","volume":"19","author":"Balada","year":"2009","journal-title":"Rev. Med. Virol."},{"issue":"3","key":"10.1016\/j.msard.2018.06.002_bib0003","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1212\/WNL.39.3.324","article-title":"Multiple sclerosis \u2013like illness occurring with human immunodeficiency virus infection","volume":"39","author":"Berger","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.06.002_bib0004","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1742-4690-6-104","article-title":"B cells and monocytes from patients with active multiple sclerosis exhibit increased surface expression of both HERV-H Env and HERV-W Env, accompanied by increased seroreactivity","volume":"6","author":"Brudek","year":"2009","journal-title":"Retrovirology"},{"key":"10.1016\/j.msard.2018.06.002_bib0005","volume":"41","author":"Charcot","year":"1868"},{"issue":"January (1)","key":"10.1016\/j.msard.2018.06.002_bib0006","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1600-065X.2011.01076.x","article-title":"Molecular mimicry as an inducing trigger for CNS autoimmune demyelinating disease","volume":"245","author":"Chastain","year":"2012","journal-title":"Immunol. Rev."},{"issue":"3","key":"10.1016\/j.msard.2018.06.002_bib0007","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/rmv.465","article-title":"Association of human endogenous retroviruses with multiple sclerosis and possible interactions with herpes viruses","volume":"15","author":"Christensen","year":"2005","journal-title":"Rev. Med. Virol."},{"issue":"September (9133)","key":"10.1016\/j.msard.2018.06.002_bib0008","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(05)60075-X","article-title":"Expression of sequence variants of endogenous retrovirus RGH in particle form in multiple sclerosis","volume":"352","author":"Christensen","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2018.06.002_bib0009","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1136\/jnnp.51.10.1249","article-title":"The 150th anniversary of the first depiction of the lesions of multiple sclerosis","volume":"51","author":"Compston","year":"1988","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2018.06.002_bib0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/jnnp-2014-307932","article-title":"HIV and lower risk of multiple sclerosis: beginning to unravel a mystery using a record-linked database study","volume":"86","author":"Gold","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2018.06.002_bib0011","doi-asserted-by":"crossref","unstructured":"Goodin D.S. The causal cascade to multiple sclerosis: a model for MS pathogenesis PLoS One 4 2009; e4565. February (2) 26.","DOI":"10.1371\/journal.pone.0004565"},{"key":"10.1016\/j.msard.2018.06.002_bib0012","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-065X.2012.01134.x","article-title":"The genetics of multiple sclerosis: an up-to-date review","volume":"248","author":"Gourrand PA Harbo","year":"2012","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.msard.2018.06.002_bib0013","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12977-016-0301-x","article-title":"Contribution of type W human endogenous retroviruses to the human genome: characterization of HERV-W proviral insertions and processed pseudogenes","volume":"13","author":"Grandi","year":"2016","journal-title":"Retrovirology"},{"issue":"April (8745)","key":"10.1016\/j.msard.2018.06.002_bib0014","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/0140-6736(91)92580-U","article-title":"Just another dubious virus in cells from a patient with multiple sclerosis?","volume":"337","author":"Haahr","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2018.06.002_bib0015","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jns.2017.07.027","article-title":"Retroviral envelope proteins: involvement in neuropathogenesis","volume":"380","author":"Hansen","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2018.06.002_bib0016","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.coviro.2015.09.007","article-title":"S. Epstein-Barr Virus latency: current and future perspectives","volume":"14","author":"Kempkes","year":"2015","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.msard.2018.06.002_bib0017","first-page":"18","article-title":"Meeting report","volume":"15","author":"Kremer","year":"2017"},{"key":"10.1016\/j.msard.2018.06.002_bib0018","doi-asserted-by":"crossref","unstructured":"Liedthe M.D., Ryan Tomlin C., Lockhart S.M., et al. 2014. Longterm efficacy and safety of raltegravir in the management of HIV infection infect drug resist. 7, 73\u201384.","DOI":"10.2147\/IDR.S40168"},{"issue":"9","key":"10.1016\/j.msard.2018.06.002_bib0019","doi-asserted-by":"crossref","first-page":"e44991","DOI":"10.1371\/journal.pone.0044991","article-title":"Expression and activation by Epstein Barr virus of human endogenous retroviruses-W in blood cells and astrocytes: inference for multiple sclerosis","volume":"7","author":"Mameli","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.msard.2018.06.002_bib0020","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1111\/j.1468-1331.2011.03430.x","article-title":"Could antiretroviral drugs be effective in multiple sclerosis? A case report","volume":"18","author":"Maruszak","year":"2011","journal-title":"Eur. J. Neurol."},{"issue":"September (3)","key":"10.1016\/j.msard.2018.06.002_bib0021","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/cei.12133","article-title":"Flow cytometric assay detecting cytotoxicity against human endogenous retrovirus antigens expressed on cultured multiple sclerosis cells","volume":"173","author":"M\u00f8ller-Larsen","year":"2013","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.msard.2018.06.002_bib0022","article-title":"The association between human endogenous retroviruses and multiple sclerosis: a systematic review and meta-analysis","volume":"12","author":"Morandi E. Tanasescu","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2018.06.002_bib0023","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/0140-6736(91)92579-Q","article-title":"Isolation of retroviruses from patients with multiple sclerosis","volume":"337","author":"Perron","year":"1991","journal-title":"Lancet"},{"issue":"March (9)","key":"10.1016\/j.msard.2018.06.002_bib0024","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1073\/pnas.1100213108","article-title":"T-cell expansion during chronic viral infection is dependent on endogenous retroviral superantigens","volume":"108","author":"Punkosdy","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.msard.2018.06.002_bib0025","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1136\/jnnp.70.4.494","article-title":"Clinical trials of multiple sclerosis monitored with enhanced MRI; new sample size calculations based on large data sets","volume":"70","author":"Sormani","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818301792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818301792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:43:28Z","timestamp":1761900208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818301792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":25,"alternative-id":["S2211034818301792"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.06.002","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}